SCHEMBL5367116

SCHEMBL5367116

O=C(O)c1cc(Cl)ccc1Cc1cccc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.50
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.49
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CTBP2 P56545 1/20 0.46
MEN1 O00255 1/20 0.46
CYP3A4 P08684 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
KMT2A Q03164 1/20 0.46
HIF1A Q16665 1/20 0.46
HSD17B10 Q99714 1/20 0.46
DCLRE1B Q9H816 1/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
APEX1 P27695 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5357513 0.88 PPARG (0.46) HCAR2ALDH1A1TP53CA1CA2
SCHEMBL7374000 0.87 TSHR (0.57) HCAR2ALDH1A1CA1CA2CTBP2
Cyclopropane SCHEMBL27582578 0.86 RXRA (0.49) HCAR2HIF1ADCLRE1BRXRARXRB
SCHEMBL27853748 0.84 ALDH1A1 (0.61) ALDH1A1TP53CA1CA2MEN1
SCHEMBL5365504 0.82 HSP90AA1 (0.53) ALDH1A1MEN1HPGDALOX15KMT2A
SCHEMBL11322770 0.81 PTPN1 (0.51) HCAR2ALDH1A1CTBP2MEN1CYP3A4
SCHEMBL4084814 0.80 PTGER4 (0.61) HCAR2ALDH1A1CTBP2DCLRE1BRXRA
SCHEMBL13316485 0.77 CYP3A4 (0.54) ALDH1A1TP53MEN1CYP3A4HPGD
SCHEMBL979351 0.77 HPGD (0.62) ALDH1A1TP53CA1CA2MEN1
SCHEMBL2601330 0.76 DCLRE1B (0.51) ALDH1A1CTBP2MEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663979-B1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2013-10-09 EP disclosed
US-7238714-B2 Aryl or heteroaryl amide compounds PFIZER JAPAN, INC. (JP) 2007-07-03 US disclosed
EP-1663979-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2006-06-07 EP disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 HCAR2 122/4885ALDH1A1 860/4885TP53 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.